US panel to review Valeant and GSK's anti-epileptic
This article was originally published in Scrip
Executive Summary
The US FDA has scheduled a panel meeting for Valeant Pharmaceuticals and GlaxoSmithKline's anti-epileptic candidate, retigabine (which has been renamed ezogabine, per USAN Council) as an adjunctive therapy for patients with partial-onset seizures. The peripheral and central nervous system drugs advisory committee is due to meet to discuss the therapy on 11 August.